Oxidative bioactivation of amodiaquine (AQ) by cytochrome P450s to a reactive quinoneimine is considered as an important mechanism underlying its idiosyncratic hepatotoxicity. However, because internal exposure to its major metabolite Ndesethylamodiaquine (DEAQ) is up to 240-fold higher than AQ, bioactivation of DEAQ might significantly contribute to covalent binding. The aim of the present study was to compare the kinetics of bioactivation of AQ and DEAQ by human liver microsomes (HLM) and to characterize the CYPs involved in bioactivation of AQ and DEAQ.
Introduction
Amodiaquine (AQ), a 4-aminoquinoline antimalarial drug, has been widely used in the endemic areas of Africa and Asia for more than 50 years. As an antimalarial drug, AQ has a higher efficacy compared with other 4-aminoquinoline antimalarial drugs [3] . For example, AQ shows efficacy against chloroquine-resistant strains of Plasmodium falciparum [4] and was proposed to replace chloroquine as the first line drug in Africa. However, severe idiosyncratic agranulocytosis and hepatotoxicity occurring in 1 of 2000 patients overshadow the therapeutic advantages of AQ [5] [6] [7] . This eventually led to either the withdrawal of AQ in several countries or the prohibition of usage as single administration or as prophylaxis [8] . Identification of the risk factors underlying these adverse drug reactions might assist in protection of susceptible patients against AQ toxicity. Although the exact mechanisms of these idiosyncratic reactions remain to be established, oxidative bioactivation to protein-reactive metabolites is considered to play an important role [9] [10] [11] .
After oral administration, AQ is rapidly absorbed and metabolized by CYP2C8 to N-desethylamodiaquine (DEAQ), its major stable metabolite [12] . Other minor metabolites identified in the circulation include N-bisdesethylamodiaquine (bis-DEAQ) and 2-hydroxyl-desethylamodiaquine ( Figure 1 ) [13, 14] . Because of its rapid conversion to DEAQ, and the fact that DEAQ has a 20-to 50-fold longer half-life than AQ, the area-under-curve (AUC) of DEAQ is 100-to 240-fold higher when compared to that of AQ [15] [16] [17] . Therefore, although in vitro pharmacological studies showed that AQ is about three-fold more potent than DEAQ, the antimalarial activity of AQ will be mainly determined by DEAQ [13] .
Besides the formation of stable metabolites, it has been demonstrated that AQ is bioactivated to reactive metabolites in vitro and in vivo [9, 18, 19] . Based on the structure of a glutathione (GSH) conjugate identified in rat bile, the reactive metabolite was identified as amodiaquine quinoneimine (AQ-QI) resulting from dehydrogenation of the 4-aminophenol moiety ( Figure 1 ). Covalent binding of AQ-QI to cellular macromolecules therefore is considered to be involved in the immune-mediated toxicity of AQ [19, 20] . Although covalent binding of radiolabeled AQ to liver microsomes appeared to result mainly from autoxidation [9, 21] , cytotoxicity to hepatocytes and neutrophils appeared to be strongly dependent on bioactivation to AQ-QI by cytochrome P450 and myeloperoxidase, respectively [22] [23] [24] .
Although P450-dependent bioactivation of AQ by human liver microsomes (HLM) has been demonstrated previously [25, 26] , bioactivation of DEAQ has not yet been studied. Furthermore, the individual human cytochrome P450s (hCYPs) involved in bioactivation of AQ and DEAQ have not yet been characterized. Because the expression level and activity of hepatic hCYPs can vary strongly among the population [27, 28] , overexpression of bioactivating hCYPs may be important risk factors determining individual susceptibility to AQ-induced toxicity. Recently, the extrahepatic isoforms CYP1A1, CYP1B1 and CYP2J2 were shown to bioactivate both AQ and DEAQ to their corresponding quinoneimines, as demonstrated by trapping experiments with N-acetyl cysteine as nucleophile [29] . However, the activity of the hepatic hCYPs have not been reported yet. The aims of the present study were: (1) to study and characterize the kinetics of bioactivation of AQ and DEAQ in HLM; and (2) to identify the hCYP isozymes involved in the bioactivation of AQ and DEAQ using recombinant hCYPs and by incubations of HLM in presence of specific inhibitors. Formation of reactive metabolites was determined by trapping and quantitative measurement of GSH conjugates of AQ and DEAQ from incubation samples. 
Methods

Materials
Identification and structural elucidation of GSH conjugates of AQ and DEAQ
The GSH conjugate of AQ was synthesized chemically as described by Harrison et al. [18] . The GSH conjugate of DEAQ (DEAQ-SG) was prepared biosynthetically by performing a large scale incubation of DEAQ, GSH and a drug metabolizing mutant of bacterial CYP102A1 [30] , as detailed in the Supplemental Information. After isolation of the GSH-conjugates of AQ and DEAQ by preparative highperformance liquid chromatography (HPLC), their purity and identity were determined by analytical HPLC-UV and LC-time-of-flight (TOF)-mass spectrometry (MS; see Section 2.6), and by 1 H-nuclear magnetic resonance (NMR) spectroscopy. 1 H-NMR spectra were recorded on a Bruker
Avance 500 (Fallanden, Switzerland) operating at 500.1 MHz to characterize the structure of the GSH conjugates. The 1 H-NMR spectrum of the GSH-conjugate of AQ
Figure 1
Previously identified metabolites of amodiaquine and N-desethylamodiaquine. Question markers indicate pathways to be characterized in the present study was identical to that published previously [18] , and corresponds to a GSH-conjugate with the GSH-moiety attached to the C′5-position of AQ. The biosynthetical GSH conjugate of DEAQ showed almost identical chemical shifts and coupling patterns of aromatic protons, when compared to those of AQ-SG, and is therefore also consistent with a GSH-moiety attached to the C′5-position of DEAQ (see Figure S1 and Table S1 ). The H-H correlation spectroscopy spectrum confirmed the structure of DEAQ-SG (see Figure S2 ).
Characterization of enzyme kinetics of oxidative metabolism of AQ and DEAQ by HLM glucose-6-phosphate, and 0.5 U ml À1 glucose-6-phosphate dehydrogenase. To determine involvement of autoxidation, incubations of AQ and DEAQ without NRS were performed. Reactions were terminated by the addition of ice-cold perchloric acid, final concentration 1% (v/v), and cooled on ice for 10 min. Precipitates were removed by centrifugation for 15 min at 14 000 rpm. The supernatants were analyzed by HPLC-UV and HPLC-TOF-MS, as described in Section 2.6. After correction for autoxidation, enzyme kinetical parameters were calculated by nonlinear regression using the Michaelis-Menten equation using GraphPad Prism 5 software (San Diego, CA, USA).
Incubations of AQ and DEAQ with recombinant human CYPs
Incubations of AQ and DEAQ with recombinant human CYPs were conducted in 100 mmol l -1 potassium phosphate buffer (pH 7.4) containing 5 mmol l -1 GSH, 2 mmol l -1 EDTA and 5 mmol l -1 MgCl 2 at a final volume of 100 μl in duplicate.
Each individual recombinant human CYP was incubated at a concentration of 100 nmol l -1 at 37°C in presence of AQ at 10 μmol l -1 and 100 μmol l -1 and DEAQ at 5 μmol l -1 and 50 μmol l -1 , respectively. Incubation times for AQ and DEAQ were 10 and 60 min, respectively. The reactions were initiated and terminated as described above. The supernatants were analyzed by HPLC-UV, as described in Analytical methods.
Effect of specific inhibitors of hCYPs on metabolite formation in incubations of AQ and DEAQ with HLM
To identify the hCYPs involved in oxidative metabolism of AQ and DEAQ, incubations were performed with HLM (1 mg ml -1 ) in the presence or absence of isoenzyme-specific inhibitors. Incubations were performed in 100 mmol l -1 potassium phosphate buffer (pH 7.4, containing 5 mmol l ) to investigate the involvement of human P4501A2, P4502C8, P4502C9, P4502C19, P4502D6, P4502E1 and P4503A4, respectively [31] . All inhibitors except DDC were dissolved in methanol. Concentrations of methanol in all incubations were kept below 0.5% (v/v). All reactions were initiated by the addition of NRS as described above, except incubations containing mechanism-based inhibitor DDC. DDC was preincubated for 15 min in the presence of NRS before the addition of AQ or DEAQ. Reactions with AQ proceeded for 10 min and with DEAQ proceeded for 60 min regarding the product formation linearity and then terminated with ice-cold perchloric acid at a final concentration of 1% (v/v). After centrifugation, supernatants were analyzed by HPLC-UV as described in Analytical methods.
Analytical methods
After centrifugation of terminated incubations, the supernatants were analyzed by reverse-phase LC using a Phenomenex Luna 5-μm C18 column (4.6 × 150 mm) as stationary phase, protected by a 4.0 × 3.0 mm i.d. security guard (5 μm) C18 guard column from Phenomenex (Torrance, CA, USA). An isocratic method (9% acetonitrile in 5 mmol l -1 of ammonium acetate buffer, pH 2.4, adjusted by formic acid) was used for the separation of AQ and DEAQ related metabolites. The flow rate was 0.75 ml min À1 and the UV detector was set at 342 nm. To quantify metabolites, standard curves were constructed for AQ-SG (ranging from 0.05 to 5 μmol l The LC-MS system used for metabolite identification consisted of an Agilent 1200 Series Rapid resolution LC system connecting to a TOF Agilent 6230 mass spectrometer, equipped with electrospray ionization source, and operating in the positive mode. Metabolites were separated using a Phenomenex Luna 5 μm C18 column and a gradient constructed of eluent A (5 mmol l 
Results
Identification and structural elucidation of AQ and DEAQ metabolites from HLM incubations
To identify all stable metabolites and GSH conjugates, AQ and DEAQ were first incubated with HLM in the presence of 5 mmol l -1 GSH. As shown in Figure 2A , Figure S3 . The retention time and mass spectrum was identical to that of the biosynthetic GSH-conjugate of DEAQ, with the GSH-moiety attached to the C′5-position. Next to DEAQ-SG, only a minor amount of bis-DEAQ was found, indicating that, in contrast to AQ, N-deethylation is a minor pathway compared to the bioactivation pathway.
Characterization of enzyme kinetics of AQ and DEAQ bioactivation by HLM Figure 3A shows the concentration dependency of formation of DEAQ with AQ concentrations varying from 1 to 100 μmol l -1 . As expected, the corresponding Eadie-Hofstee plot (insert Figure 3A) exhibits monophasic behavior, since N-deethylation of AQ is considered CYP2C8-specific [12] . By applying nonlinear regression according to the MichaelisMenten equation, the enzyme kinetical parameters found were: K m , 13.3 AE 1.9 μmol l -1 , V max , 1609 AE 73 pmol min À1 mg
À1
and CL int , 120.6 μl min À1 mg À1 (Table 1 ). Figure 3B shows the concentration dependent formation of AQ-SG in HLM after correction for the contribution of autoxidation of AQ. Between 10 and 100 μmol l Autoxidation was also observed for DEAQ and accounted for approximately 10-20% of formation of DEAQ-SG. Figure 3C shows concentration dependency of DEAQ-SG formation in incubations of HLM with DEAQ ranging from 1 to 50 μmol l -1 , after correction for the contribution of autoxidation. The enzyme kinetic parameters calculated using nonlinear regression were: K m , 6.1 AE 
Activity of recombinant hCYPs in the bioactivation of AQ and DEAQ
To identify the individual hCYPs involved in the bioactivation of AQ and DEAQ, incubations were conducted with recombinant hCYP isozymes at AQ concentrations of 10 and 100 μmol l -1 , and at DEAQ concentrations of 5 and 50 μmol l -1 in order to study the contributions of P450
isozymes under non-saturated and saturated conditions. Consistent with previous studies [12] , the major metabolite in AQ incubations, DEAQ, was produced at highest activity by CYP2C8 and to a lesser extent by CYP2D6 at both AQ concentrations, Figure 4A . As shown in Figure 4B , multiple recombinant CYPs were active in the formation of AQ-SG at both 10 and 100 μmol l -1 . Among them, CYP2J2 and CYP2D6 appeared the most active isoforms, followed by CYP2C8 and CYP3A4. All other recombinant hCYPs show <10% activity under 10 μmol l -1 AQ and <19% under 100 μmol l -1 AQ, when compared to the most active enzyme CYP2J2. The formed AQ-SG in control samples at both 10 and 100 μmol l -1 AQ were below the detection limit, indicating that the autoxidation of AQ under these conditions was negligible. Similar to AQ, multiple CYPs also showed activity in the bioactivation of DEAQ, Figure 4C . Recombinant CYP2D6 appeared to be the most active enzyme at both substrate concentrations. At 5 μmol l -1 DEAQ, CYP2C9 also showed 
Effect of isozyme-selective inhibitors on the bioactivation of AQ and DEAQ by HLM
Based on the enzyme kinetic parameters, inhibition experiments with HLM were performed at 10 μmol l -1 of AQ and 5 μmol l -1 of DEAQ, respectively, to get substrate concentrations in the range of the K m values. Figure 5 shows the percentage of inhibition by specific CYP inhibitors on the bioactivation of AQ and DEAQ and the detailed values of the inhibitory effects are shown in Figure 5A ). In incubations of HLM with DEAQ, the formation of DEAQ-SG was moderately inhibited by selective CYP2C8, CYP2D6 and CYP3A4 inhibitors by 19.7%, 29.1%, and 23.6%, respectively ( Figure 5B ). The combined inhibition of CYP2C8, CYP2D6 and CYP3A4 showed the strongest inhibition of 69.4% of DEAQ-SG formation compared to corresponding control incubations. Although the recombinant CYP2C9 showed the second highest activity, inhibition of CYP2C9 only gave a minor decrease of 10.7% regarding the formation of DEAQ-SG.
Discussion
The aim of present study was to characterize the kinetics of bioactivation of AQ and DEAQ by HLM in order to evaluate which compound will have the highest contribution to covalent binding to hepatic tissue. In addition, which hCYP isozymes contribute to bioactivation of AQ and DEAQ was investigated.
Previous studies showed that AQ is prone to autoxidation, leading to covalent binding to HLM even in absence of the cofactor NADPH [9, 21] . In the present study, we confirmed this finding by observation of AQ-SG formation in incubations of HLM in absence of NRS. In addition, DEAQ also showed the potency of autoxidation in incubations without NRS. However, addition of NRS resulted in a three-to ninefold strong increase in formation of AQ-SG and DEAQ-SG, dependent on substrate concentration ( Figure S4) . Also, the fact that addition of a mixture of P450-inhibitors to HLM could decrease formation of AQ-SG by more than 80% ( Figure 4A ) only can be explained by inhibition of P450-dependent bioactivation, since these inhibitors lack antioxidant properties (data not shown). Similarly, in incubations of AQ with recombinant hCYPs, formation of AQ-SG showed large differences in formation of GSH-conjugates, which would not be expected if bioactivation would mainly occur by autoxidation. Although the contribution of autoxidation in our in vitro experiments ranged to 30% in incubations with 1 mg ml À1 of HLM, the average concentration of microsomal proteins of 128 human livers was reported to be 39.46 mg g À1 liver [32] . Therefore, because of this almost 40-fold higher enzyme concentration the bioactivation of AQ and DEAQ will be mainly P450-dependent in vivo. Since the peak concentration of DEAQ is more than 20-fold higher than that of AQ itself after oral administration of AQ, whereas the half-life of DEAQ is much longer, the internal exposure to DEAQ is up to 240-fold higher than that of AQ, when considering the ratio AUC DEAQ /AUC AQ [16] . The much shorter half-life of AQ is explained by the more rapid oxidative metabolism by hepatic enzymes. As shown in Figure 2 , AQ was metabolized for 50% by HLM within 10 min, whereas DEAQ was metabolized for only 5% after 45 min. Because of the much higher internal exposure to DEAQ, and the fact that bioactivation appears to be the major pathway of oxidative metabolism, an enzyme kinetical analysis of the bioactivation pathways was performed to estimate difference in internal exposure to the quinonimines of AQ and DEAQ. Since the maximal plasma concentrations of AQ and DEAQ found clinically are in the range of 50 nmol l -1 (AQ) and 1.5-2 μmol l -1 (DEAQ), the intrinsic clearances CL int and the local substrate concentration will determine the rate by which their corresponding quinonimines will be produced. Although the CL int of DEAQ-SG formation appeared to be 5.7-fold lower compared to that of AQ-SG formation, the fact that the DEAQ concentration is over 40 times higher, and also present for a longer time because of it long half-life, implies that the overall internal exposure to chemically reactive quinonimine of DEAQ will be much higher compared to that of AQ. Because the body burden of covalent binding is considered an important risk factor for idiosyncratic drug reactions [33] , DEAQ probably not only determines the pharmacological effect of AQ-treatment, but also may determine its toxic side effects. To better understand the interindividual variability in susceptibility to AQ-induced hepatotoxicity, identification of the hCYPs involved in bioactivation of AQ and DEAQ is important. As shown in Figure 4 , multiple recombinant hCYPs appeared to be active in bioactivation of AQ and DEAQ. For AQ, highest activity in formation of AQ-SG was observed with recombinant CYP2D6 and CYP2J2, while significant activity was also found with CYP2C8 and CYP3A4. When considering the different expression levels of hCYPs in human liver (Table 3) , the largest contribution to bioactivation of AQ in the average liver is expected from CYP3A4, CYP2D6 and CYP2C8, in decreasing order. The strong inhibition observed by the inhibitors of CYP2C8 (QCT) and CYP3A4 (KTZ) in incubations with HLM confirmed their contribution to bioactivation of AQ. However, the contribution of CYP2D6 in hepatic bioactivation appears to be overpredicted when based on supersomes expressing CYP2D6, since no significant inhibition of HLM-catalyzed bioactivation of AQ was observed with the CYP2D6-specific inhibitor QND.
For DEAQ, which overall may cause a higher degree of covalent binding to that of AQ, as described above, also several recombinant hCYPs showed activity in bioactivation to its quinonimine ( Figure 4C ). At the low concentration of DEAQ, the highest amount of DEAQ-SG was found with recombinant CYP2D6 and CYP2C9, whereas CYP3A4, CYP2C19 and CYP2C8 also showed significant activity at 50 μmol l -1 DEAQ.
Considering the different expression levels of these CYPs in the average human liver, CYP2C9, CYP2D6 and CYP3A4 were predicted to contribute significantly to DEAQ bioactivation, which appear to be confirmed by the inhibition study with P450-specific inhibitors. Although so-called "intersystem extrapolation factors" [34] have been used to improve extrapolation of activities of recombinant enzymes to that of HLM, it was decided not to include this in the present study because prediction of relative contributions of individual hCYPs in the average human liver, might not be representative for the relative contribution of hCYPs in the liver of susceptible individuals.
As shown by the meta-analysis of Achour et al. [28] , extremely large variabilities occur in the level of hepatic CYPs, which may be due to genetic factors, enzyme induction and epigenetic factors. For almost each CYP individuals have been identified with up to 10-fold higher hepatic levels than present in the average liver, Table 3 . The very large variability in CYP2C8 expression, the main enzyme involved in oxidative metabolism of AQ, probably underlies the variability in pharmacokinetics of AQ. Individuals with high levels of CYP3A4, CYP2C8, CYP2C9 and CYP2D6 will be exposed to higher levels of quinonimines of AQ and DEAQ. The meta-analysis of Achour et al. [28] , showed significant correlations between abundance of CYP3A4 and CYP2C8 and between CYP3A4 and CYP2C9. This may be partially explained by the fact that these enzymes are inducible, mediated by the same transcription factors. This implicates that individuals with high expression levels of all three CYP isoforms might be exposed to an increased risk of AQ-induced toxicity.
Identification of CYPs involved in oxidative metabolism of AQ and DEAQ may not only explain interindividual differences in pharmacokinetics, but also explain the consequences of drug-drug interactions caused by drugs administered simultaneously. AQ is often administered together with other antimalarial drugs, such as artesunate, and antiretroviral drugs, such as nevirapine [17] and Table 1 Enzyme kinetic parameters of formation of N-desethylamodiaquine (DEAQ) and C′5-glutathionly-amodiaquine (AQ-SG) from amodiaquine and of C′5-glutathionly-N-desethylamodiaquine (DEAQ-SG) formation from DEAQ in human liver microsomes efavirenz [35] . A pharmacokinetic interaction study between efavirenz and amodiaquine/artesunate, was prematurely discontinued because the first two of the five healthy volunteers developed strong increases in plasma transaminase levels [35] . Efavirenz is known to cause enzyme induction of CYP3A4 and CYP2B6 in humans [36, 37] . A strong increase in CYP3A4-dependent bioactivation of AQ and DEAQ therefore may explain the hepatic damage observed in these volunteers. Since artesunate is mainly metabolized by CYP2A6, drug-drug interaction between artesunate and AQ or DEAQ is unlikely to occur [38] . However, both artemisinin and dehydroartemesinin have been shown to induce CYP3A4 in human hepatocytes, which may lead to increased bioactivation of AQ and DEAQ when coadministered [39] .
In conclusion, based on the present study covalent binding by the quinoneimine of both AQ and DEAQ might significantly contribute to the hepatotoxicity observed in a small subgroup of AQ-treated patients, several human CYPs, such as CYP3A4, CYP2D6, CYP2C8 and CYP2C9 appear to be involved in bioactivation of AQ and DEAQ to 
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